SOURCE: UV Flu Technologies, Inc.

UV Flu Technologies, Inc.

October 05, 2010 09:00 ET

UV Flu Technologies Announces Development of Residential Market Bacteria Killing Indoor Air Purifier to Be Based on Laboratory Proven Design

Smaller Home Unit to Deliver Health Benefits Based on Success of Commercial Grade UV-400

CENTERVILLE, MA--(Marketwire - October 5, 2010) - UV Flu Technologies, Inc. (OTCBB: UVFT) (the "Company") is pleased to announce that in response to interest from the marketplace, the company intends to rapidly roll out the development of a residential sector air purifier offering features specifically designed for the residential marketplace. The new unit will be designated UV-200 and will be designed with the needs of the health-conscious homeowner in mind.

"Our current UV-400 air purifier sets a very high standard, and is unique in the marketplace, but was primarily conceived for the demands of the commercial marketplace," said Jack Lennon, President of UV Flu Technologies. "Our UV-400 kills airborne bacteria in larger spaces up to 700-900 sq. feet, whereas typical HEPA filter units generally cover a space from 100-200 sq. feet. Our unit keeps on killing contaminants long after the filter units have lost their efficacy as they are not dependent on changing, or washing filters continuously."

Mr. Lennon further notes, "Doctors have provided feedback to us that indicated they were reluctant to recommend air filters to their patients, because if the patients did not faithfully change or wash the filters at prescribed intervals, they could end up getting sicker from the infected air leaving the unit through the dirty filter. Our technology uses Hi Intensity Germicidal UV light, which kills organic contaminants that pass through the unit and isn't dependent on a filter medium that captures, but doesn't kill, bacteria and other contaminants."

"Our residential unit will use the same technology, but will be designed for smaller spaces, and will incorporate new features to make it easier to transport from room-to-room, such as between children's bedrooms. The UV-200 as planned, will offer features designed specifically for allergy relief, as well. We look forward to making these units available as soon as possible and invite interested individuals to contact us today to find out more," said Mr. Lennon.

Further details regarding the Company's business, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database.

About UV Flu Technologies, Inc. (OTCBB: UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector. The Company manufactures the ViraTech UV-400, which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria at rates exceeding 99.2% on a first-pass basis. ViraTech UV-400 is a Class II medical device and is available without a prescription. 

Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.


UV Flu Technologies, Inc.
John J. Lennon, President & CEO

Contact Information